Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refers to cells that have traits of both hormone-producing endocrine cells and nerve cells. These cells release hormones into the blood in response to a signal from the nervous system. Hormones are biological substances that circulate through the bloodstream to control the activity of other organs or cells in the body. Lutetium Lu 177-dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Treatment with Lutetium Lu 177 dotatate may shrink the tumor in a way that can be measured in patients with metastatic prostate cancer with neuroendocrine differentiation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z rakiem prostaty, który dał przerzuty do innych części ciała.
- •Rak prostaty musi wykazywać cechy komórek neuroendokrynnych.
- •Pacjenci mają ukończone 18 lat.
- •Ogólny stan zdrowia pacjenta pozwala na udział w badaniu (dobra kondycja fizyczna).
- •Odpowiednie wyniki badań krwi (liczba białych krwinek, płytek krwi, poziom hemoglobiny).
- •Prawidłowe funkcjonowanie wątroby i nerek.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 14, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (13)
City of Hope Comprehensive Cancer Center
Duarte, United States
Los Angeles General Medical Center
Los Angeles, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
Northwestern University
Chicago, United States
University of Kentucky/Markey Cancer Center
Lexington, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, United States
Wake Forest University Health Sciences
Winston-Salem, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, United States
UT MD Anderson Cancer Center
Houston, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, United States
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, United States
Trial contact
Site Public Contact
Abhishek Tripathi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jacek Pinski
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Maha H. Hussain
PRINCIPAL_INVESTIGATOR
Site Public Contact
Zin W. Myint
PRINCIPAL_INVESTIGATOR
Site Public Contact
Michael A. Carducci
PRINCIPAL_INVESTIGATOR
Site Public Contact
Michael McCormack
PRINCIPAL_INVESTIGATOR
Site Public Contact
Edmund Folefac
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ana Aparicio
PRINCIPAL_INVESTIGATOR
Site Public Contact
John M. Floberg
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.